UnitedHealthcare ERT Coverage Policy Update

Coverage Criteria

VPRIV (velaglucerase) - Type 1 (initial and continuation)

VPRIV is proven and medically necessary for Type 1 Gaucher disease when ALL criteria are met.

Initial therapy criteria: Diagnosis of Type 1 Gaucher disease; symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); dosing is in accordance with U.S. Food and Drug Administration (FDA) approved labeling; initial authorization will be for no more than 12 months.

VPRIV is the preferred enzyme replacement therapy.

Continuation therapy criteria: Documentation of positive clinical response to therapy (e.g., reduced severity or resolution of anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); dosing is in accordance with FDA approved labeling; continuation authorization will be for no more than 12 months.

VPRIV is the preferred enzyme replacement therapy.

VPRIV (velaglucerase) - Type 1 continuation

Continuation of VPRIV for Type 1 is medically necessary when ALL criteria are met.

Elelyso (taliglucerase) - Type 1

Elelyso is medically necessary for Type 1 when ALL criteria are met.

Initial therapy criteria: Diagnosis of Type 1 Gaucher disease; symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); and one of the following: history of failure of VPRIV due to failure to meet clinical goals despite VPRIV therapy, or history of failure of VPRIV due to hypersensitivity to VPRIV therapy; dosing is in accordance with FDA approved labeling; initial authorization will be for no more than 12 months.

Elelyso requires prior VPRIV failure or hypersensitivity for Type 1.

Cerezyme (imiglucerase) - Type 1

Cerezyme is medically necessary for Type 1 when ALL criteria are met.

Initial therapy criteria: Diagnosis of Type 1 Gaucher disease; symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); and one of the following: history of failure of VPRIV due to failure to meet clinical goals despite VPRIV therapy, or history of failure of VPRIV due to hypersensitivity to VPRIV therapy; dosing is in accordance with FDA approved labeling; initial authorization will be for no more than 12 months.

Cerezyme requires prior VPRIV failure or hypersensitivity for Type 1.

VPRIV (velaglucerase) - Type 3

VPRIV is medically necessary for Type 3 when ALL criteria are met.

Continuation therapy criteria: Documentation of positive clinical response to therapy (e.g., reduced severity or resolution of anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); dose does not exceed 60 units/kg every 2 weeks; continuation authorization will be for no more than 12 months.Dose ≤ 60 U/kg every 2 weeks

Cerezyme (imiglucerase) - Type 3

Cerezyme is medically necessary for Type 3 when ALL criteria are met.

Initial therapy criteria: Diagnosis of Type 3 Gaucher disease; symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); and one of the following: history of failure of VPRIV due to failure to meet clinical goals despite VPRIV therapy, or history of failure of VPRIV due to hypersensitivity to VPRIV therapy; dose does not exceed 60 units/kg every 2 weeks; initial authorization will be for no more than 12 months.Dose ≤ 60 U/kg every 2 weeks

Cerezyme requires prior VPRIV failure or hypersensitivity for Type 3 per policy structure.

Continuation therapy criteria: Documentation of positive clinical response to therapy (e.g., reduced severity or resolution of anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); dose does not exceed 60 units/kg every 2 weeks; continuation authorization will be for no more than 12 months.Dose ≤ 60 U/kg every 2 weeks

Coverage Rationale (editorial changes)

Summary of change to coverage rationale wording

Editorial revisions: Language changed to remove the adjective 'proven' from prior statements that Cerezyme and Elelyso are 'proven and medically necessary' for Type 1, and that Cerezyme is 'proven and medically necessary' for Type 3; the underlying criteria remain unchanged.

See full policy for complete criteria and context.

The codes listed in this policy are provided for reference only. Listing a code does not imply the service described is covered or that reimbursement is guaranteed. Benefit coverage is determined by applicable federal, state, or contractual requirements and other policies and guidelines; the inclusion of a code is informational and not an authorization to bill or a guarantee of payment.

Clinical guidance and professional society reviews indicate there is no evidence that enzyme replacement therapy (ERT) improves neurological features in Type 2 Gaucher disease. Accordingly, ERT should not be offered for treatment of the neurologic manifestations of Type 2, and management for these patients should emphasize supportive care.

Professional guidance recommends that ERT should not be initiated in asymptomatic patients who carry genotypes that increase risk for neuronopathic involvement. Treatment decisions for individuals at risk for neuronopathic disease should be guided by the presence of non-neurological, symptomatic manifestations rather than genotype alone.

Applicable Codes & Dosing Notes

Applicable Codesmixed

J1786	Injection, imiglucerase, 10 units
J3060	Injection, taliglucerase alfa, 10 units
J3385	Injection, velaglucerase alfa, 100 units
E75.22	Gaucher Disease

Codes mentionedmixed

No CPT/HCPCS, ICD-10, NDC, or modifier codes are listed in this document fragment.

VPRIV (velaglucerase) — Type 3 dosing limit

VPRIV Type 3 dose capDose does not exceed 60 units/kg every 2 weeks for both initial and continuation therapy

Initial authorization durationInitial authorization will be for no more than 12 months

Continuation requirementsContinuation requires documentation of positive clinical response and dose ≤ 60 units/kg every 2 weeks

ERT dosing comparison — typical dosing ranges

Cochrane dosing summaryERT given at 30–45 units/kg every 2–4 weeks was generally as effective as 60 units/kg for assessed outcomes during the first year of treatment

Typical lower-range regimen

Provider Actions & Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for enzyme replacement therapy for Gaucher disease. Initial and continuation authorizations are each limited to no more than 12 months per authorization period.

Prior authorization required
Initial and continuation authorizations limited to <= 12 months

Documentation Required

Initial Authorization — Required Documentation

For initial authorization, submit documentation that includes: diagnosis (Type 1 or Type 3 Gaucher disease as applicable), evidence of symptomatic disease (for example: moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly), dosing consistent with FDA‑approved labeling (or dose limits specified in policy such as VPRIV ≤ 60 units/kg every 2 weeks for Type 3), and the specific drug requested.

Diagnosis and symptomatic disease documentation required

Definitions

Type 1 Gaucher disease — definition & prevalence

DefinitionType 1 Gaucher disease: most common subtype (>90%), systemic manifestations without primary central nervous system involvement (nonneuronopathic)

Typical manifestationsAnemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly

Prevalence noteAccounts for more than 90% of all Gaucher disease cases

Type 2 Gaucher disease — acute neuronopathic

DefinitionType 2 Gaucher disease: acute neuronopathic disease with severe early neurologic manifestations and death usually occurring before 2 years of age

Clinical courseRapid neurologic deterioration in infancy

Initial Therapy Criteria

Initial therapy

Initial therapy criteria by product and disease type.

VPRIV Type 1 initial: Diagnosis of Type 1 Gaucher disease; symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); dosing is in accordance with FDA approved labeling; initial authorization will be for no more than 12 months.

VPRIV is the preferred enzyme replacement therapy.

Elelyso Type 1 initial: Diagnosis of Type 1 Gaucher disease; symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); and one of the following: history of failure of VPRIV due to failure to meet clinical goals despite VPRIV therapy, or history of failure of VPRIV due to hypersensitivity to VPRIV therapy; dosing per FDA labeling; initial authorization will be for no more than 12 months.

Elelyso requires prior VPRIV failure or hypersensitivity for Type 1.

Cerezyme Type 1 initial: Diagnosis of Type 1 Gaucher disease; symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); and one of the following: history of failure of VPRIV due to failure to meet clinical goals despite VPRIV therapy, or history of failure of VPRIV due to hypersensitivity to VPRIV therapy; dosing per FDA labeling; initial authorization will be for no more than 12 months.

Continuation Criteria

Continuation therapy

Continuation authorizations across products.

General continuation: Documentation of positive clinical response to therapy (e.g., reduced severity or resolution of anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); dosing is in accordance with FDA approved labeling; continuation authorization will be for no more than 12 months.

Applies to Cerezyme, Elelyso, and VPRIV where continuation criteria are specified.

Therapy Change from Imiglucerase to Velaglucerase Alfa

Data supporting switching from imiglucerase to velaglucerase alfa.

Switch from imiglucerase to velaglucerase alfa: In a multicenter, open-label 12-month study (n = 40) patients previously stable on imiglucerase switched to velaglucerase alfa at an equal dose and maintained stable hemoglobin, platelet counts, and organ volumes through 12 months; velaglucerase alfa was generally well tolerated.

Most infusions were every other week; most patients tolerated home infusion without important side effects.

Step Therapy / Product Preference

Step	Preferred product / requirement	Alternatives and requirement
1
VPRIV (velaglucerase) — preferred initial therapy for Type 1 and Type 3 when all product-specific criteria are met (diagnosis of relevant Gaucher type, symptomatic disease, dosing per FDA labeling; initial authorization ≤ 12 months).
Cerezyme (imiglucerase) or Elelyso (taliglucerase) — permitted only after documented failure of VPRIV to meet clinical goals (e.g., persistent anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly) or documented hypersensitivity to VPRIV. For Type 3, Cerezyme is allowed only after VPRIV failure or hypersensitivity per policy structure.

Evidence summary	Implication for step therapy
Cochrane review (2015) found different recombinant glucocerebrosidases to be bio-similar and non-inferior in safety and efficacy for surrogate biological response parameters during the first year of treatment; dosing of 30–45 units/kg every 2–4 weeks was generally as effective as 60 units/kg for assessed outcomes.
Although clinical evidence indicates multiple recombinant enzymes have similar efficacy, the policy maintains VPRIV as the preferred initial product and requires documented VPRIV failure or hypersensitivity before authorizing Cerezyme or Elelyso; the evidence does not mandate a strict step sequence but supports clinical interchangeability considerations.

Site of Care

Billing Rule

Site‑of‑care recommendation: first three infusions in clinical site

Initial infusions (the first three) should be administered at a clinical site (home, office, or infusion center); if no adverse events occur, subsequent infusions may be given at an alternative site per investigator or patient status.

Protocol from trials: all patients received their first three infusions at the clinical site; alternative site permitted thereafter if tolerated.

Note

Home infusions observed as well tolerated in switch studies

In multicenter switch studies most patients received subsequent infusions at home without important side effects observed.

Study details: n = 40 switched patients; velaglucerase alfa was generally well tolerated and most patients received infusions at home.

Background

Gaucher disease is caused by an autosomal recessive deficiency of the lysosomal enzyme glucocerebrosidase, leading to accumulation of glucocerebroside in liver, spleen, bone marrow and other tissues. Clinical subtypes differ by neurologic involvement: Type 1 is the nonneuronopathic form with primarily visceral and hematologic manifestations, Type 2 is the acute neuronopathic form with early severe neurologic disease and high early mortality, and Type 3 is the chronic neuronopathic form with subacute neurologic findings plus systemic disease. Enzyme replacement therapy (ERT) and substrate reduction therapies effectively reverse visceral manifestations, but evidence does not support benefit of ERT for central nervous system involvement in Type 2 (and data are limited for neurologic benefit in Type 3), so therapy is selected based on systemic manifestations and clinical need.

OpenPayer

Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease

Coverage Criteria

Applicable Codes & Dosing Notes

Provider Actions & Authorization

Definitions

Initial Therapy Criteria

Continuation Criteria

Step Therapy / Product Preference

Site of Care

Background